Altimmune, Inc.

101 articles about Altimmune, Inc.

• Altimmune to Participate at Two Upcoming Investor Conferences - May 8, 2023

  5/8/2023

  Altimmune, Inc. today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.

• Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

  5/4/2023

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update.

• Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B

  4/11/2023

  Altimmune, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB).

• Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

  3/27/2023

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors.

• 

  Altimmune Obesity Drug Well-Positioned Despite Safety Data

  3/22/2023

  Mayank Mamtani, managing director and group head of healthcare research at B. Riley Securities, told BioSpace he believes Altimmune's pemvidutide still shows promise despite safety concerns.

• Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

  3/21/2023

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from a Week 24 interim analysis of 160 subjects in its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide along with the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with obesity or overweight and type 2 diabetes.

• Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

  2/21/2023

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

• Altimmune Appoints Raymond Jordt as Chief Business Officer

  1/4/2023

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023.

• Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

  1/4/2023

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023.

• Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

  12/20/2022

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.

• Altimmune to Participate at Two Upcoming Investor Conferences - November 22, 2022

  11/22/2022

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual Conference Tuesday, November 29, 2022 Fireside chat at 10:55 am Eastern Time.

• Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

  11/10/2022

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three and nine months ended September 30, 2022, and provided a business update.

• Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10

  11/3/2022

  Altimmune, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.

• Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®

  10/28/2022

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022.

• Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

  9/28/2022

  Altimmune, Inc. today announced the completion of first dosing of all subjects in its Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide 1 in subjects with obesity or overweight.

• Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update

  8/11/2022

  Altimmune, Inc. today announced financial results for the three and six months ended June 30, 2022, and provided a business update.

• Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11

  8/4/2022

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update.

• 

  Nasal Spray Vaccines for COVID-19: a Viable Option or Too Little, Too Late?

  7/27/2022

  SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.

• Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022Presentation to be highlighted in the Best of International Liver Congress

  6/17/2022

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress TM 2022, to be held in London, UK on June 22-26, 2022.

• Altimmune to Participate at Two Upcoming Investor Conferences

  6/3/2022

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022.